ABSTRACT
We studied how combination antiviral therapy affects B cell abnormalities associated with HIV-1 infection, namely elevated circulating immunoglobulin (Ig)G antibody-secreting cell (ASC) frequencies and hypergammaglobulinemia. Within a few weeks of starting antiviral therapy, there is a marked decline in IgG-ASC frequency in both acutely and chronically infected people, whereas the hypergammaglobulinemia often present during chronic infection is more gradually resolved. These reductions are sustained while HIV-1 replication is suppressed. HIV-1 antigen-specific B cell responses are also affected by therapy, manifested by a rapid decline in circulating gp120-specific ASCs. Anti-gp120 titers slowly decrease in chronically infected individuals and usually fail to mature in acutely infected individuals who were promptly treated with antiretroviral therapy. Long-term nonprogressors have high titer antibody responses to HIV-1 antigens, but no detectable gp120-specific IgG-ASC, and normal (or subnormal) levels of total circulating IgG-ASC. Overall, we conclude that HIV-1 infection drives B cell hyperactivity, and that this polyclonal activation is rapidly responsive to decreases in viral replication caused by combination antiviral therapy.
Subject(s)
Antiviral Agents/therapeutic use , B-Lymphocytes/immunology , HIV Antibodies/immunology , HIV Antigens/immunology , HIV Infections/immunology , HIV-1/isolation & purification , Antiviral Agents/pharmacology , Drug Therapy, Combination , HIV Infections/drug therapy , HumansABSTRACT
Heterotrophic organisms generally face a trade-off between rate and yield of adenosine triphosphate (ATP) production. This trade-off may result in an evolutionary dilemma, because cells with a higher rate but lower yield of ATP production may gain a selective advantage when competing for shared energy resources. Using an analysis of model simulations and biochemical observations, we show that ATP production with a low rate and high yield can be viewed as a form of cooperative resource use and may evolve in spatially structured environments. Furthermore, we argue that the high ATP yield of respiration may have facilitated the evolutionary transition from unicellular to undifferentiated multicellular organisms.
Subject(s)
Adenosine Triphosphate/metabolism , Biological Evolution , Fermentation , Models, Biological , Oxygen Consumption , Animals , Bacteria/growth & development , Bacteria/metabolism , Carbohydrate Metabolism , Dictyostelium/growth & development , Dictyostelium/metabolism , Energy Metabolism , Fungi/growth & development , Fungi/metabolism , Mathematics , Oxidation-Reduction , Oxidative Phosphorylation , ThermodynamicsABSTRACT
Traditionally, the interest of population and evolutionary biologists in infectious diseases has been almost exclusively in their role as agents of natural selection in higher organisms. Recently, this interest has expanded to include the genetic structure and evolution of microparasite populations, the mechanisms of pathogenesis and the immune response, and the population biology, ecology, and evolutionary consequences of medical and public health interventions. This article describes recent work in these areas, emphasizing the ways in which quantitative, population-biological approaches have been contributing to the understanding of infectious disease and the design and evaluation of interventions for their treatment and prevention.
Subject(s)
Biological Evolution , Infections/microbiology , Parasitic Diseases/parasitology , Animals , Bacterial Physiological Phenomena , Drug Resistance, Microbial , Humans , Infections/immunology , Molecular Epidemiology , Parasites/genetics , Parasites/physiology , Parasitic Diseases/immunology , Population Dynamics , Vaccination , Virus Physiological PhenomenaABSTRACT
Studies of lymphocyte turnover in animal models have implications for understanding the mechanism of cell killing and the extent of lymphocyte regeneration in human immunodeficiency virus infection. Quantitative analyses of the sequential changes in bromodeoxyuridine labeling of CD4 and CD8 T lymphocytes not only revealed the normal proliferation and death rates of these cell populations in uninfected macaques, but also showed a substantial increase in these rates associated with simian immunodeficiency virus (SIV) infection. Faster labeling and delabeling in memory and naïve T lymphocyte subpopulations as well as in NK (natural killer) and B cells were also observed in infected macaques, suggesting a state of generalized activation induced by SIV.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Simian Acquired Immunodeficiency Syndrome/immunology , T-Lymphocyte Subsets/immunology , Animals , Bromodeoxyuridine/metabolism , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/pathology , CD8-Positive T-Lymphocytes/pathology , Cell Death , Cell Division , Humans , Kinetics , Lymphocyte Activation , Lymphocyte Count , Macaca mulatta , Mathematics , Models, Biological , Regression Analysis , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/physiology , T-Lymphocyte Subsets/pathology , Viral LoadABSTRACT
Although cytotoxic T lymphocytes (CTLs) are thought to be involved in the control of human immunodeficiency virus-type 1 (HIV-1) infection, it has not been possible to demonstrate a direct relation between CTL activity and plasma RNA viral load. Human leukocyte antigen-peptide tetrameric complexes offer a specific means to directly quantitate circulating CTLs ex vivo. With the use of the tetrameric complexes, a significant inverse correlation was observed between HIV-specific CTL frequency and plasma RNA viral load. In contrast, no significant association was detected between the clearance rate of productively infected cells and frequency of HIV-specific CTLs. These data are consistent with a significant role for HIV-specific CTLs in the control of HIV infection and suggest a considerable cytopathic effect of the virus in vivo.
Subject(s)
HIV Infections/immunology , HIV Infections/virology , HIV-1/physiology , Lymphocyte Count/methods , RNA, Viral/blood , T-Lymphocytes, Cytotoxic/immunology , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Coloring Agents , Cytopathogenic Effect, Viral , Cytotoxicity, Immunologic , Flow Cytometry , Gene Products, gag , Gene Products, pol , HIV Infections/drug therapy , HIV-1/genetics , HLA-A Antigens , Humans , Oligopeptides , Sensitivity and Specificity , Viral Load , ViremiaABSTRACT
Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to suppression of HIV-1 plasma viremia to undetectable levels for 3 or more years. However, adherence to complex drug regimens can prove problematic, and subjects may temporarily discontinue HAART for variable periods. We studied 6 HIV-1-infected individuals who stopped therapy. Off HAART, levels of viremia were suppressed to fewer than 500 copies/mL in 2 subjects for more than 12 and more than 24 months, respectively, and in 1 subject for 4 months on 1 occasion. Three subjects failed to contain plasma viremia. Broad and strong HIV-1-specific immune responses were detected in subjects with prolonged suppression of viral replication. This longitudinal study suggests that containment of HIV-1 replication to low or undetectable levels after discontinuation of HAART is associated with strong virus-specific immune responses. Boosting of HIV-1-specific immune responses should be considered as an adjunctive treatment strategy for HIV-1-infected individuals on HAART.
Subject(s)
Acquired Immunodeficiency Syndrome/immunology , Anti-HIV Agents/therapeutic use , HIV-1/immunology , Virus Replication , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/virology , Adult , HIV Core Protein p24/immunology , Humans , Male , Middle Aged , T-Lymphocytes, Cytotoxic/immunology , Viremia/drug therapy , Viremia/immunologyABSTRACT
OBJECTIVE: To investigate the optimal time point for the initiation of therapy in HIV infection from the perspective of drug resistance. BACKGROUND: The enormous genetic diversity of HIV within an infected individual represents one of the greatest challenges for effective therapy, because the viral population may harbour drug-resistant mutants that rapidly outgrow the wild-type virus once the patient starts treatment. To determine the optimal timing of therapy it is crucial to know how long it takes for the viral population to build up sufficient diversity to enable the virus to escape from therapy. METHOD: A stochastic model of the viral diversification during primary infection was used to study the behaviour of small population sizes of mutant virus. RESULTS AND CONCLUSIONS: The simulations suggest that from the perspective of viral diversity, therapy should be started at the viral set-point. Starting treatment earlier involves a risk of the selective outgrowth of drug-resistant mutants, which are transiently present at the viral peak during primary infection.
Subject(s)
Anti-HIV Agents/therapeutic use , Drug Resistance, Microbial/genetics , HIV Infections/drug therapy , HIV-1/genetics , HIV Infections/virology , HIV-1/drug effects , Humans , Mutation , Stochastic Processes , Time Factors , Viremia/virology , Virus ReplicationABSTRACT
OBJECTIVE: To calculate the expected prevalence of resistant HIV mutants before antiviral therapy. DESIGN: HIV replication generates virus mutants. The prevalence of these mutants is determined by mutation and selection/fitness. Some mutations will confer drug resistance and it is crucial for the success of antiviral drug therapy to determine whether these resistant viruses are present before the initiation of therapy. METHODS: A quasispecies equation was used to calculate the expected frequency of drug-resistant virus prior to therapy. RESULTS AND CONCLUSIONS: We show how the pretreatment frequency of resistant virus depends on the number of point mutations between wild-type and mutant virus, the selective disadvantage of the resistant mutant and the intermediate mutants, and the mutation rate.
Subject(s)
Anti-HIV Agents/pharmacology , HIV-1/drug effects , HIV-1/genetics , Point Mutation , Drug Resistance, Microbial/genetics , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/physiology , Humans , Mathematics , Models, Biological , Viral LoadABSTRACT
BACKGROUND: Structured interruptions of antiretroviral therapy of HIV-1 infected individuals are currently being tested in clinical trials to study the effect interruptions have on the immune responses and control of virus replication. OBJECTIVE: To investigate the potential risks and benefits of interrupted therapy using standard population dynamical models of HIV replication kinetics. METHODS: Standard population dynamical models were used to study the effect of structured therapy interruptions on the immune effector cells, the latent cell compartment and the emergence of drug resistance. CONCLUSIONS: The models suggest that structured therapy interruption only leads to transient or sustained virus control if the immune effector cells increase during therapy. This increase must more than counterbalance the increase in susceptible target cells induced by therapy. The risk of inducing drug resistance by therapy interruptions or the risk of repopulating the pool of latent cells during drug-free periods may be small if the virus population remains at levels considerably below baseline. However, if the virus load increases during drug-free periods to levels similar to or higher than baseline before therapy, both these risks increase dramatically.
Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/drug therapy , HIV-1 , Models, Theoretical , Drug Administration Schedule , Drug Resistance, Microbial , HIV Infections/virology , Humans , Risk Assessment , T-Lymphocytes, Cytotoxic , Virus LatencyABSTRACT
BACKGROUND: Some individuals with chronic HIV-1 infection have discontinued their drug therapy with consequent plasma virus rebound. In a small number of patients, a delayed or absent rebound in plasma virus load has been noted after drug cessation, apparently associated with prior drug interruptions and autologous boosting of HIV-1 specific immune responses. We hypothesized that cyclic structured treatment interruptions structured treatment interruptions (STI) could augment HIV-1 specific immune responses in chronic HIV-1 infection, which might help to control HIV-1 replication off therapy. METHODS: We initiated an STI pilot study in 10 antiretroviral treatment-naive HIV-1 chronically infected subjects with baseline CD4 T-cell counts > 500 x 10(6) cells/l and plasma viral load > 5000 copies/ml who received highly active antiretroviral therapy (HAART) for 1 year with good response (plasma viral load < 20 copies/ml for at least 32 weeks). Three cycles of HAART interruption were performed. RESULTS: In all of the patients viral load rebounded, but doubling times increased significantly between the first and third stops (P = 0.008), and by the third stop, six out of nine subjects had a virological set-point after a median 12 months off therapy that was lower than baseline before starting HAART (ranging from 0.6 log(10) to 1.3 log(10) lower than baseline) and in four it remained stable below 5000 copies/ml. Those subjects who controlled viral replication developed significantly stronger HIV-1 specific cellular immune responses than subjects lacking spontaneous decline (P < 0.05). During viral rebounds no genotypic or phenotypic changes conferring resistance to reverse trancriptase inhibitors or protease inhibitors was detected, but mean absolute CD4 T-cell counts declined significantly, although never below 450 x 10(6)/l and the mean value at 12 months off therapy was significantly higher than the pre-treatment level (P = 0.004). CONCLUSIONS: Our findings suggest that STI in chronic HIV-1 infection might augment HIV-1-specific cellular immune responses associated with a spontaneous and sustained drop in plasma viral load in some subjects but at the potential cost of lower CD4 T-cell counts.
Subject(s)
HIV Infections/drug therapy , HIV-1/drug effects , Adult , Antiretroviral Therapy, Highly Active , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Chronic Disease , Drug Administration Schedule , HIV Infections/immunology , HIV Infections/virology , HIV-1/growth & development , HIV-1/immunology , Humans , Middle Aged , Pilot Projects , Viral LoadABSTRACT
There is a large body of theoretical studies that investigate factors that affect the evolution of virulence, that is parasite-induced host mortality. In these studies the host population is assumed to be genetically homogeneous. However, many parasites have a broad range of host types they infect, and trade-offs between the parasite virulence in different host types may exist. The aim of this paper is to study the effect of host heterogeneity on the evolution of parasite virulence. By analyzing a simple model that describes the replication of different parasite strains in a population of two different host types, we determine the optimal level of virulence in both host types and find the conditions under which strains that specialize in one host type dominate the parasite population. Furthermore, we show that intrahost evolution of the parasite during an infection may lead to stable polymorphisms and could introduce evolutionary branching in the parasite population.
Subject(s)
Biological Evolution , Host-Parasite Interactions/genetics , Virulence/genetics , Animals , Genetics, Population , Models, Genetic , Parasitic Diseases/genetics , Parasitic Diseases/parasitology , Polymorphism, Genetic , Selection, GeneticABSTRACT
Antiviral treatment of HIV-1 infection often fails because of the rapid emergence of resistant virus within weeks of the start of therapy. This raises the question of whether resistant viruses pre-exist in drug-naive patients or whether it is produced after the start of therapy. Here we compare the likelihood of pre-existence with the likelihood of production of resistant virus during therapy. We show that provided resistant virus pre-exists, then a stronger therapy may lead to a greater initial reduction of virus load, but will also cause a faster rise of resistant virus. In this case the total benefit of treatment is independent of the degree of inhibition of sensitive virus. If, on the other hand, resistant mutants do not pre-exist, then the emergence of resistance during treatment depends on the efficacy of the drug. If the drug is sufficiently potent to eradicate sensitive virus, then the probability that resistant mutants first appear during therapy is smaller than the probability that they existed before therapy. If the drug cannot eradicate the sensitive virus, then after sufficiently long time resistant mutants will appear. However, mutants that are unlikely to pre-exist may taken long time to appear.
Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/therapeutic use , Drug Resistance, Microbial , HIV-1/drug effects , Models, Biological , Acquired Immunodeficiency Syndrome/virology , Anti-HIV Agents/pharmacology , CD4-Positive T-Lymphocytes/immunology , Humans , Mathematics , Time FactorsABSTRACT
We used a mathematical model to evaluate the hypothesis that parasites and pathogens with long living propagules should evolve high levels of virulence, i.e. high rates of pathogen-induced host mortality. Our model shows that the optimal level of virulence is independent of the longevity of the propagules either: (i) if the density or the prevalence of infected hosts is in (or fluctuates around) equilibrium; or (ii) if the death rate of the infected host population is high compared with that of the propagules. The level of virulence that maximizes the parasite's fitness (Multhusian parameter) increases with increasing longevity of its propagules only if the host-parasite system has not reached equilibrium and the death rate of the propagules is high relative to that of the infected hosts. Therefore, for parasites that have recently invaded a susceptible host population, greater propagule longevity may initially favour higher virulence; but once the equilibrium is reached the optimal virulence is independent of propagule longevity.
Subject(s)
Biological Evolution , Parasites/genetics , Parasites/pathogenicity , Virulence/genetics , Animals , Egypt , History, 20th Century , History, Ancient , Humans , Mathematics , Models, Biological , Parasitic Diseases/etiology , Parasitic Diseases/history , Time FactorsABSTRACT
The mechanisms that lead to maintenance of an active effector cytotoxic T-cell (CTL) response in Human Immunodeficiency Virus type-1 (HIV-1) infection are not well understood. We have investigated the role of antigen in maintenance of an HIV-1 specific CTL response by studying a patient (313-7) whose antigenic stimulus was reduced using antiretroviral drug therapy started within 90 days of HIV-1 infection. This patient made a primary monospecific CTL response to an HLA-C*0802 restricted epitope in nef (KAAVDLSHFL) prior to treatment. Within 7 days of starting treatment the nef specific CTL precursor frequency (CTLp) had decreased from 60/10(6) to 4/10(6) peripheral blood mononuclear cells (PBMC), coincident with a decline in viremia from 18 470 to 615 copies/ml. Both plasma viremia and nef specific CTLp remained at low levels for 180 days. The nef-specific CTL clone T-cell receptor (TCR) mRNA transcripts also decreased after treatment, but clone specific TCR DNA persisted. It appears that removal of antigen alters the state of HIV specific CTL from an activated effector population (detected in the CTLp assay and by measurement of clone specific RNA) to a non-activated quiescent population (detected by measurement of clone-specific DNA). This latter population may represent persisting HIV specific memory CTL.
Subject(s)
Anti-HIV Agents/therapeutic use , Gene Products, nef/immunology , HIV Infections/immunology , HIV Protease Inhibitors/therapeutic use , HIV-1/immunology , Receptors, Antigen, T-Cell/genetics , Reverse Transcriptase Inhibitors/therapeutic use , T-Lymphocytes, Cytotoxic/immunology , Adult , DNA , Drug Therapy, Combination , HIV Infections/drug therapy , Humans , Kinetics , Male , RNA, Messenger , nef Gene Products, Human Immunodeficiency VirusABSTRACT
We review some crucial aspects of drug therapy and viral resistance that have been investigated within the framework developed for the modelling of virus kinetics. First, we give a general overview on the use of mathematical models in the field of HIV research. We seek to identify the factors that determine the steady state virus load and show that stable reductions during antiviral therapy are difficult to explain within the standard model of virus dynamics. We discuss possible extensions that enable the models to account for the moderately reduced virus loads during non-suppressive treatment and argue that the residual viremia under suppressive treatment can probably be attributed to the survival of long-lived infected cells, rather than to new rounds of replication. Next, we address the emergence of resistance during suppressive therapy and demonstrate that the resistant virus is more likely to be present already at the start of treatment than to be generated during therapy. The appearance of resistance after a prolonged period of initial suppression indicates that drug efficacy is not continuously maintained over time. We investigate the potential risks and benefits of therapy interruptions. Considering the effect of recombination, we argue that it probably decelerates, rather than accelerates the evolution of multidrug-resistant virus. We also review state-of-the-art methods for the estimation of fitness, which is crucial to the understanding of the emergence of resistance during therapy or the re-emergence of wild type upon the cessation of therapy.
Subject(s)
Anti-HIV Agents/pharmacology , HIV Infections/virology , HIV-1/physiology , Models, Biological , Antiretroviral Therapy, Highly Active , Drug Resistance, Viral , HIV Infections/drug therapy , HIV-1/genetics , Humans , Mutation , Viral LoadSubject(s)
HIV Infections/virology , HIV-1/physiology , Antigenic Variation , Biological Evolution , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/immunology , Disease Progression , Genetic Variation , HIV Antibodies/immunology , HIV Antigens/immunology , HIV Infections/immunology , HIV-1/genetics , HIV-1/immunology , Humans , T-Lymphocytes, Cytotoxic/immunology , Viral Load , Virus ReplicationABSTRACT
The growing problem of resistance to antimicrobial chemotherapy was discussed by participants at the February 1995 workshop at Emory University on population biology, evolution, and control of infectious diseases. They discussed the nature and source of this problem and identified areas of research in which information is lacking for the development of programs to control of the emergence and spread of resistant bacteria. Particular attention was given to theoretical (mathematical modeling) and empirical studies of the within and between-host population biology (epidemiology) and the evolution of microbial resistance to chemotherapeutic agents. Suggestions were made about the kinds of models and data needed, and the procedures that could be employed to stem the ascent and dissemination of resistant bacteria. This article summarizes the observations and recommendations made at the 1995 meeting and in the correspondence between participants that followed. It concludes with an update on the theoretical and empirical research on the between- and within-host population biology and evolution of resistance to antimicrobial chemotherapy most of which has been done since that meeting.
Subject(s)
Bacterial Infections/drug therapy , Communicable Disease Control , Drug Resistance, Microbial , Bacteria/drug effects , Bacteria/genetics , Bacterial Infections/epidemiology , Bacterial Infections/prevention & control , Biological Evolution , Epidemiologic Methods , Humans , Models, TheoreticalABSTRACT
Mathematical models have become an increasingly valuable tool in HIV research. In particular, the mathematical analysis of drug-induced perturbations of the steady-state viral load in chronically infected patients has led to fundamental new insights into HIV dynamics in vivo and demonstrated that there is highly active viral replication throughout the course of infection. The same models can be used to address issues related to drug resistance and may eventually provide theoretical guidelines for the design of efficient treatment strategies. The goal of this article is to illustrate to a readership with nonmathematical background how these models work, what key assumptions they make, and which questions they may help to answer.